We’re excited to share that Biocyten will attend the 6th Oligonucleotides for Central Nervous System (CNS) Summit from August 19th - 21st in Boston, MA. With advancements in oligo technologies, it is now possible to tap into the potential of previously undruggable CNS targets. Come meet our team to learn more about Biocytogen’s comprehensive portfolio of neurological disease animal models and extensive behavior testing platform.
What is the 6th Oligonucleotides for CNS Summit?
The 6th Oligonucleotides for CNS Summit will bring together 160+ professionals to exchange insights and actionable strategies on the development of novel RNA-targeted therapies for CNS disorders. It will feature in depth discussions and presentations, covering emerging data and the latest delivery approaches. You won’t want to miss this fantastic opportunity to network and collaborate with industry experts.
Event Overview
Date: August 19th - 21st, 2026
Venue: The Colonnade Hotel, 120 Huntington Ave, Boston, MA 02116
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
